Underlying Mechanisms of Obesity-induced Obstructive Sleep Apnea
Launched by BRANDON NOKES · Mar 9, 2021
Trial Information
Current as of August 20, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Obstructive sleep apnea (OSA) is a highly prevalent disease with major neurocognitive and cardiovascular sequelae. Obesity is a major risk factor for OSA, but the underlying mechanisms remain unclear. Given the rising prevalence of obesity and the lack of adequate therapies for some afflicted patients, further mechanistic work is clearly required. Bariatric surgery is being done increasingly with compelling outcome data emerging; however, clinical response to weight loss is highly variable. In some patients, OSA is not present at baseline, despite morbid obesity, in other patients, OSA reso...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • - Men and women
- • Ages \>= 18-65 years old
- • BMI 35 kg/m2--and above
- • Scheduled for sleeve gastrectomy (bariatric surgery)
- Exclusion Criteria:
- • Any cardiovascular, pulmonary or renal disease other than well-controlled hypertension or asthma.
- • Pregnancy
- • Currently smoking
- • Any respiratory disorder other than OSA or well controlled asthma
- • contraindication to MRI
About Brandon Nokes
Brandon Nokes is a dedicated clinical trial sponsor with a commitment to advancing medical research and improving patient outcomes. With a focus on innovative therapeutic solutions, Brandon Nokes collaborates with healthcare professionals and research institutions to design and implement rigorous clinical trials. The organization prioritizes ethical standards, patient safety, and scientific integrity, ensuring that all studies are conducted with the highest level of quality and compliance. Through strategic partnerships and a patient-centered approach, Brandon Nokes aims to contribute valuable insights to the medical community and drive the development of new treatment options.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
La Jolla, California, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials